The typical presentation of oesophageal cancer is with dysphagia. Our existing data shows that a 2-week chemoradiotherapy protocol (30Gy/10# with concurrent carboplatin and paclitaxel) is well tolerated and provides rapid dysphagia relief. We hypothesise that the radiotherapy interventions given in PALEO will be immune priming, and hence that multimodality treatment including checkpoint inhibition will enhance disease control at all tumour sites.
The PALEO clinical trial enrols patients with oligometastatic oesophageal cancer and dysphagia. The aim is to determine the activity of durvalumab given concurrently with chemoradiotherapy to the primary oesophageal cancer and stereotactic radiotherapy to a single metastasis.
A/Prof Amitesh Roy
Wednesday, 15 November
Session 1: Upper GI and HPB Cancer (Advanced) – Progress in trials and management